Amgen Announces Webcast for 2026 Third Quarter Financial Results
Amgen has scheduled a webcast to discuss its financial results for the third quarter of 2026.
Stocks · News reference
FDA Reviews Amgen's Video for VECTIBIX Injection
The FDA's Office of Prescription Drug Promotion determined that a submitted video for Amgen's VECTIBIX injection was false or misleading.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight
The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.
Regeneron and Amgen Narrow Scope of Eylea Biosimilar Lawsuit
Regeneron Pharmaceuticals and Amgen have reached an agreement to narrow the scope of their ongoing legal dispute regarding Eylea biosimilars.